Author + information
- Received July 25, 2014
- Revision received August 18, 2014
- Accepted August 22, 2014
- Published online February 1, 2015.
- Alessandra Dei Cas, MD, PhD∗,
- Sadiya S. Khan, MD†,
- Javed Butler, MD, MPH‡,
- Robert J. Mentz, MD§,
- Robert O. Bonow, MD, MS‖,
- Angelo Avogaro, MD, PhD¶,
- Diethelm Tschoepe, MD#,
- Wolfram Doehner, MD, PhD∗∗,
- Stephen J. Greene, MD‖,
- Michele Senni, MD††,
- Mihai Gheorghiade, MD‖ and
- Gregg C. Fonarow, MD‡‡∗ ()
- ∗Unit of Diabetes and Prevention of Associated Diseases, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
- †Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
- ‡Cardiology Division, Stony Brook University, Stony Brook, New York
- §Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
- ‖Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois
- ¶Department of Medicine, University of Padova, Padova, Italy
- #Heart and Diabetes Center North Rhine Westfalia, University Clinic of the Ruhr University, Bochum, Germany
- ∗∗Center for Stroke Research, Charite Universitätsmedizin, Berlin, Germany
- ††Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
- ‡‡Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California Medical Center Los Angeles, Los Angeles, California
- ↵∗Reprint requests and correspondence:
Dr. Gregg C. Fonarow, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, 10833 LeConte Avenue, Room 47-123 CHS, Los Angeles, California 90095-1679.
The prevalence of patients with concomitant heart failure (HF) and diabetes mellitus (DM) continues to increase with the general aging of the population. In patients with chronic HF, prevalence of DM is 24% compared with 40% in those hospitalized with worsening HF. Patients with concomitant HF and DM have diverse pathophysiologic, metabolic, and neurohormonal abnormalities that potentially contribute to worse outcomes than those without comorbid DM. In addition, although stable HF outpatients with DM show responses that are similar to those of patients without DM undergoing evidence-based therapies, it is unclear whether hospitalized HF patients with DM will respond similarly to novel investigational therapies. These data support the need to re-evaluate the epidemiology, pathophysiology, and therapy of HF patients with concomitant DM. This paper discusses the role of DM in HF patients and underscores the potential need for the development of targeted therapies.
Dr. Butler is a consultant for Amgen, Bayer, Celladon, GE Healthcare, Medtronic, Takeda, and Trevena. Dr. Mentz has consulting relationships with Bristol-Myers Squibb, GlaxoSmithKline, and Novartis. Dr. Gheorghiade is a consultant for Bayer, Novartis, Takeda, Cardiocell, and Johnson & Johnson. Dr. Fonarow has consulting relationships with Novartis, Medtronic, Amgen, Bayer, Boston Scientific, Johnson & Johnson, and The Medicines Co.; and is a consultant for Agency for Healthcare Research and Quality and National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 25, 2014.
- Revision received August 18, 2014.
- Accepted August 22, 2014.
- American College of Cardiology Foundation